CY1113710T1 - Βελτιωση παραγωγης πρωτεϊνης - Google Patents

Βελτιωση παραγωγης πρωτεϊνης

Info

Publication number
CY1113710T1
CY1113710T1 CY20131100014T CY131100014T CY1113710T1 CY 1113710 T1 CY1113710 T1 CY 1113710T1 CY 20131100014 T CY20131100014 T CY 20131100014T CY 131100014 T CY131100014 T CY 131100014T CY 1113710 T1 CY1113710 T1 CY 1113710T1
Authority
CY
Cyprus
Prior art keywords
pkd
cert
protein production
reduces
lipid
Prior art date
Application number
CY20131100014T
Other languages
English (en)
Inventor
Hitto Kaufmann
Lore Florin
Eric Becker
Monilola Olayioye
Angelika Hausser
Tim Fugmann
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07103406A external-priority patent/EP1964922A1/en
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of CY1113710T1 publication Critical patent/CY1113710T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)

Abstract

Η εφεύρεση αφορά το πεδίο παραγωγής πρωτεΐνης και τεχνολογία κυτταρικής καλλιέργειας. Η CERT ταυτοποιείται ως πρωτότυπο υπόστρωμα PKD in vivo. Η φωσφορυλίωση σε σερίνη 132 από PKD μειώνει την συγγένεια της CERT για τον λιπιδικό στόχο της, 4-φωσφορική φωσφατιδυλοϊνοσιτόλη, σε μεμβράνες Golgi και μειώνει την δραστικότητα μεταφοράς κεραμιδιού, ταυτοποιώντας την PKD ως ρυθμιστή ομοιόστασης λιπιδίων. Η παρούσα εφεύρεση δείχνει ότι η CERT με την σειρά της είναι κρίσιμη για ενεργοποίηση PKD και PKD-εξαρτώμενη μεταφορά πρωτεϊνικού φορτίου στην κυτταρική μεμβράνη. Η αλληλεξάρτηση των PKD και CERT είναι επομένως καθοριστική στην διατήρηση της ακεραιότητας μεμβρανών Golgi και σε εκκριτική μεταφορά.
CY20131100014T 2007-03-02 2013-01-07 Βελτιωση παραγωγης πρωτεϊνης CY1113710T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07103406A EP1964922A1 (en) 2007-03-02 2007-03-02 Improvement of protein production
EP07104226 2007-03-15
EP07116358 2007-09-13
EP08717274A EP2126093B1 (en) 2007-03-02 2008-02-29 Improvement of protein production

Publications (1)

Publication Number Publication Date
CY1113710T1 true CY1113710T1 (el) 2016-06-22

Family

ID=39639553

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100014T CY1113710T1 (el) 2007-03-02 2013-01-07 Βελτιωση παραγωγης πρωτεϊνης

Country Status (24)

Country Link
US (4) US20130177919A1 (el)
EP (3) EP2522730A1 (el)
JP (1) JP5467415B2 (el)
KR (1) KR20100015363A (el)
AR (2) AR065573A1 (el)
AU (1) AU2008223874B2 (el)
BR (1) BRPI0808542A2 (el)
CA (1) CA2677925A1 (el)
CY (1) CY1113710T1 (el)
DK (1) DK2126093T3 (el)
EA (1) EA018190B1 (el)
ES (1) ES2397274T3 (el)
HK (1) HK1136314A1 (el)
HR (1) HRP20121077T1 (el)
IL (1) IL200030A0 (el)
MX (1) MX2009009156A (el)
MY (1) MY148472A (el)
NZ (1) NZ580043A (el)
PL (1) PL2126093T3 (el)
PT (1) PT2126093E (el)
SG (1) SG182160A1 (el)
SI (1) SI2126093T1 (el)
TW (1) TWI419902B (el)
WO (1) WO2008107388A1 (el)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2126093E (pt) 2007-03-02 2012-12-03 Boehringer Ingelheim Pharma Melhoramento da produção de proteínas
EP2334784A1 (de) * 2008-09-10 2011-06-22 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung hsa-produzierender zellen
JP2012525826A (ja) * 2009-05-05 2012-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｈｏ／ｃｅｒｔ細胞系
JP2012526536A (ja) * 2009-05-15 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング コンビナトリアルエンジニアリング
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
JP2013543381A (ja) * 2010-10-01 2013-12-05 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸およびその使用方法
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US8506797B2 (en) * 2011-04-10 2013-08-13 Therapeutic Proteins International, LLC Downstream bioprocessing device
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4015005A1 (en) 2011-10-03 2022-06-22 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
UA116194C2 (uk) 2011-10-28 2018-02-26 Протена Біосаєнсиз Лімітед Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
US8852435B2 (en) * 2011-11-29 2014-10-07 Therapeutics Proteins International, LLC Purification and separation treatment assembly (PASTA) for biological products
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
JP6342333B2 (ja) 2012-01-27 2018-06-13 プロセナ バイオサイエンシーズ リミテッド α−シヌクレインを認識するヒト化抗体
KR101438533B1 (ko) * 2012-03-30 2014-09-17 한양대학교 산학협력단 적혈구계 세포의 인 비트로 확장방법
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US8886625B1 (en) 2012-10-31 2014-11-11 Google Inc. Methods and computer-readable media for providing recommended entities based on a user's social graph
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8972368B1 (en) * 2012-12-07 2015-03-03 Google Inc. Systems, methods, and computer-readable media for providing search results having contacts from a user's social graph
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3071974A2 (en) 2013-11-19 2016-09-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
CA2938931A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
KR20160127825A (ko) 2014-03-12 2016-11-04 프로테나 바이오사이언시즈 리미티드 항-mcam 항체 및 관련된 사용 방법
EP3116907A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
TWI707949B (zh) * 2014-06-09 2020-10-21 美商健臻公司 種子罐培養法（ｓｅｅｄ ｔｒａｉｎ ｐｒｏｃｅｓｓｅｓ）及其用途
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CA2998716A1 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
AU2017259038B2 (en) 2016-05-02 2024-05-23 Prothena Biosciences Limited Antibodies recognizing Tau
JP7194985B2 (ja) 2016-05-02 2022-12-23 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018007924A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7076711B2 (ja) 2016-07-02 2022-05-30 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3478715A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018178126A1 (en) 2017-03-29 2018-10-04 Boehringer Ingelheim Rcv Gmbh & Co Kg Recombinant host cell with altered membrane lipid composition
IL270375B2 (en) 2017-05-02 2024-12-01 Prothena Biosciences Ltd Antibodies recognizing tau
JP2021502955A (ja) 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
BR112020006791A2 (pt) 2017-10-06 2020-12-01 Prothena Biosciences Limited métodos de detecção de transtirretina
AU2018350890B2 (en) * 2017-10-16 2024-07-04 Regeneron Pharmaceuticals, Inc. In situ Raman spectroscopy systems and methods for controlling process variables in cell cultures
CR20210272A (es) 2018-11-26 2021-07-14 Forty Seven Inc Anticuerpos humanizados contra c-kit
CN113544149B (zh) 2019-03-03 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
CN110592044B (zh) * 2019-07-26 2021-06-22 中国农业科学院蔬菜花卉研究所 蛋白激酶Fused编码基因及其在防治小菜蛾中的应用
CN111100865B (zh) * 2020-01-07 2022-03-18 江南大学 一种提高酿酒酵母丁醇耐受能力的方法
JP2023533458A (ja) 2020-06-24 2023-08-03 プロシーナ バイオサイエンシーズ リミテッド ソルチリンを認識する抗体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
US5869250A (en) * 1996-12-02 1999-02-09 The University Of North Carolina At Chapel Hill Method for the identification of peptides that recognize specific DNA sequences
WO2000050607A2 (en) * 1999-02-24 2000-08-31 Juan Saus Goodpasture antigen binding protein
EP1067182A3 (en) * 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
CN1511040A (zh) * 2001-05-25 2004-07-07 ����˹���ѷ��ѧ 作为多种治疗模式基础的蛋白质的选择性剪接形式
EP2314691A3 (en) 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
US7326768B2 (en) * 2003-02-05 2008-02-05 Juan Saus Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
JP2007500016A (ja) 2003-06-11 2007-01-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド 培養においてタンパク質生成を増大させるための方法
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
JP2005035926A (ja) * 2003-07-14 2005-02-10 Japan Science & Technology Agency セラミド輸送を促進する薬剤、該薬剤を製造する塩基配列、セラミド遊離を促進する活性の測定方法、及びセラミドの膜間移動を促進する活性の測定方法
JPWO2005116204A1 (ja) 2004-05-11 2008-06-19 株式会社アルファジェン Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
CN101948541B (zh) * 2005-06-20 2014-08-06 健泰科生物技术公司 用于肿瘤诊断和治疗的组合物和方法
US20090018099A1 (en) 2007-03-02 2009-01-15 Hitto Kaufmann Protein production
PT2126093E (pt) * 2007-03-02 2012-12-03 Boehringer Ingelheim Pharma Melhoramento da produção de proteínas
JP2012525826A (ja) * 2009-05-05 2012-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｈｏ／ｃｅｒｔ細胞系

Also Published As

Publication number Publication date
HRP20121077T1 (hr) 2013-01-31
EA200901168A1 (ru) 2010-06-30
JP5467415B2 (ja) 2014-04-09
US20080300207A1 (en) 2008-12-04
NZ580043A (en) 2012-04-27
EP2126093A1 (en) 2009-12-02
JP2010519917A (ja) 2010-06-10
TWI419902B (zh) 2013-12-21
US20130196430A1 (en) 2013-08-01
BRPI0808542A2 (pt) 2014-08-26
HK1136314A1 (en) 2010-06-25
MY148472A (en) 2013-04-30
PT2126093E (pt) 2012-12-03
US20130197196A1 (en) 2013-08-01
US20130177919A1 (en) 2013-07-11
MX2009009156A (es) 2009-09-04
EP2126093B1 (en) 2012-10-10
EP2522729A1 (en) 2012-11-14
EP2522730A1 (en) 2012-11-14
ES2397274T3 (es) 2013-03-05
IL200030A0 (en) 2011-08-01
SI2126093T1 (sl) 2013-01-31
DK2126093T3 (da) 2013-01-07
EA018190B1 (ru) 2013-06-28
AR086476A2 (es) 2013-12-18
US8221999B2 (en) 2012-07-17
AU2008223874B2 (en) 2014-06-26
PL2126093T3 (pl) 2013-03-29
SG182160A1 (en) 2012-07-30
AR065573A1 (es) 2009-06-17
KR20100015363A (ko) 2010-02-12
AU2008223874A1 (en) 2008-09-12
CA2677925A1 (en) 2008-09-12
TW200846368A (en) 2008-12-01
WO2008107388A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
CY1113710T1 (el) Βελτιωση παραγωγης πρωτεϊνης
CY1122123T1 (el) Συνθεσεις λιπιδικου νανοσωματιδιου και μεθοδοι για απελευθερωση mrna
EP2516681A4 (en) COMPOSITIONS AND METHOD FOR DETECTING SMALL RNAS
BR112014004543A2 (pt) método de síntese de proteínas
CY1119736T1 (el) Ανιχνευση και απαριθμηση μικροοργανισμων
CY1121657T1 (el) Μεθοδοι και συνθεσεις για κατευθυνομενη απο rna τροποποιηση dna στοχου και για κατευθυνομενη απο rna ρυθμιση της μεταγραφης
CY1119173T1 (el) Νεα μορια αναστολεα jnk
EA201101582A1 (ru) Интеллектуальная упаковка для выявления микроорганизмов
CY1117858T1 (el) Ολιγονουκλεοτιδια για την προκληση αλλαγης στην αλληλουχια rna μοριου-στοχου παροντος σε ζωντανο κυτταρο
AR077115A1 (es) Produccion de isopreno usando las vias de mevalonato (mva) y la de no mevalonato (dxp)
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
ATE515488T1 (de) Click-chemie zur herstellung von reportermolekülen
CL2013001717A1 (es) Molecula de acido nucleico que codifica un polipeptido con actividad enzimatica de una enzima hidroxifenilpiruvato dioxigenasa (hppd); metodo de produccion de una planta de soja resistente a un inhibidor de hppd y/o glufosinato; metodo de control de malezas; metodo para identificar el evento syht0h2 en una muestra; y kit de deteccion.
TR201900213T4 (tr) Bir sürekli hücre kültüründe bir polipeptit veya ilişkin virüsün üretim metodu.
BR112012030746A2 (pt) cepas hospedeiras fúngigas filamentosas e constructos de dna , e métodos de uso dos mesmos.
DE602008006382D1 (de) Pyridin-boronsäure-quencher zur verwendung in analytsensoren
BR112015017354A2 (pt) método para detectar pelo menos uma base modificada
PH12013500995A1 (en) Methods for increasing yield and fine chemical production in plants
DK1994149T3 (da) Nye fluorescerende proteiner og fremgangsmåder til anvendelse deraf
TR201907065T4 (tr) Aptamer kullanarak hedef maddeyi tespit yöntemi.
CL2013001621A1 (es) Molecula de acido nucleico reguladora con especificidad definida, construccion de expresion que la comprende, vector; microorganismo, celula vegetal o animal; y metodo para la produccion de dicha molecula.
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
BR112016025898A2 (pt) ?drimenol sintases e método para produzir drimenol?
CY1119625T1 (el) Νεα κρυσταλλικη μορφη vii της αγομελατινης, μεθοδος παρασκευης και χρηση της και φαρμακευτικη συνθεση που την περιεχει
BR112013004183A2 (pt) plantas com melhores características relacionadas ao rendimento e método para sua produção